isoxicam and Edema

Topics: Adult; Aged; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Clinical Trials as Topic; Collagen; Drug Interactions; Drug Tolerance; Edema; Half-Life; Humans; Kinetics; Muscular Diseases; Osteoarthritis; Oxygenases; Piroxicam; Rats; Thiazines

The frequencies of adverse reactions in patients younger than 65 years and 65 and older were compared for dosages of isoxicam ranging from 200 to 600 mg per day. Data were collected from the records of 2,184 patients younger than 65 years and 1,059 patients 65 years or older from controlled and open studies of patients with osteoarthritis, rheumatoid arthritis, or musculoskeletal disorders. For both age groups, the most common adverse reactions were gastrointestinal. For other adverse reactions, the frequencies were notably lower than for gastrointestinal reactions. For virtually all adverse reactions, the frequencies were similar for the two age groups. Among patients who received only the recommended dosage of 200 mg per day, the frequencies of all reactions were lower than among the entire population and were similar between the two age groups. On the basis of this study, it appears that isoxicam is equally well tolerated in patients who are younger than 65 and those 65 and older.

Topics: Aged; Aging; Arthritis, Rheumatoid; Clinical Trials as Topic; Edema; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Piroxicam; Thiazines

Topics: Adult; Aged; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Clinical Trials as Topic; Collagen; Drug Interactions; Drug Tolerance; Edema; Half-Life; Humans; Kinetics; Muscular Diseases; Osteoarthritis; Oxygenases; Piroxicam; Rats; Thiazines

The activity of 2-phenylpyrazolo-4-ethyl-4,7-dihydro [1,5a]pyrimidin-7-one (FPP028), a non-acidic, analgesic, antipyretic, and anti-inflammatory compound, was investigated in a number of pharmacological tests performed in rats. The anti-inflammatory properties of FPP028 were evaluated through the carrageenan induced paw edema and the cotton pellet induced granuloma and compared with the activity of indomethacin, phenylbutazone, and isoxicam; as a result, the activity of FPP028 was shown to be similar to that of the latter compounds. To assess the analgesic properties of FPP028 in comparison with indomethacin and phenylbutazone, the Randall and Sellitto and the mouse-writhing tests were used; in both tests, FPP028 demonstrated a significant analgesic activity. FPP028 was shown to possess antipyretic properties in the test of yeast-induced pyrexia. The gastro-erosive activity of phenylbutazone and FPP028 was studied in restraint-stressed rats; in such test the ulcerogenic activity of phenylbutazone appeared to be dose-related; conversely, FPP028 demonstrated a gastro-protective effect since the number of gastric lesions induced either by stress or phenylbutazone treatment was decreased bu FPP028. Our data show that FPP028 is endowed with most of the pharmacological properties of the classic antiinflammatory drugs. Further studies are however needed to more fully elucidate its mechanism of action because our in-vivo data indicate that FPP028 is not an inhibitor of prostaglandin biosynthesis.

Topics: Adrenalectomy; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Edema; Gastric Acid; Granuloma; Guinea Pigs; In Vitro Techniques; Indomethacin; Male; Mice; Phenylbutazone; Piroxicam; Prostaglandins; Pyrazoles; Pyrimidines; Rats; Rats, Inbred Strains; Stomach Ulcer; Thiazines